rs11568822 — APOC1 APOC1 HCR-1 promoter variant

APOC1 HCR-1 Promoter Variant — The Built-In CETP Brake

In the dense gene cluster on chromosome 19q13.32, four apolipoprotein genes — APOE, APOC1, APOC4, and APOC2 — share a pair of liver-specific regulatory elements called hepatic control regions (HCR-1 and HCR-2)¹¹ hepatic control regions (HCR-1 and HCR-2)
enhancer elements about 15 kilobases downstream of APOE that drive liver-specific expression of the entire apolipoprotein gene cluster. A common insertion variant in the APOC1 promoter region, the rs11568822 CGTT insertion (also called the HpaI polymorphism or H2 allele), fine-tunes how much apolipoprotein C-I your liver produces — and through it, how powerfully your body can inhibit a key enzyme that would otherwise drain your HDL cholesterol.

The Mechanism

Apolipoprotein C-I (apoCI) is a small, positively charged protein that travels primarily on HDL and VLDL. Its most consequential function in lipoprotein metabolism is acting as the physiological inhibitor of CETP²² physiological inhibitor of CETP
cholesteryl ester transfer protein, the enzyme that transfers cholesteryl esters from protective HDL particles to pro-atherogenic LDL and VLDL. By altering the electrostatic charge on HDL surfaces, apoCI disrupts the CETP-HDL complex and reduces cholesterol ester transfer. More apoCI means stronger CETP inhibition, which means more cholesteryl esters retained in HDL and higher measured HDL-C.

The rs11568822 variant is a 4-base-pair CGTT insertion at position -317 relative to the APOC1 transcription start site. Xu et al. (1999)³³ Xu et al. (1999)
first characterized this variant in the Journal of Lipid Research demonstrated that the insertion allele (H2) produces 50% higher APOC1 reporter gene expression in transfection studies, suggesting the insertion disrupts binding of a negative transcriptional regulator and de-represses APOC1 transcription. ApoCI also inhibits scavenger receptor BI (SR-BI)⁴⁴ scavenger receptor BI (SR-BI)
the hepatic receptor that mediates selective uptake of HDL cholesteryl esters into the liver, further preserving HDL particle integrity.

The Evidence

The foundational study Xu et al. 1999⁵⁵ Xu et al. 1999
Journal of Lipid Research genotyped 315 African-Americans and European-Americans with characterized APOE genotypes. In African-American participants who were APOE ε3/ε3 homozygotes (removing APOE confounding), H2/H2 homozygotes showed striking lipid advantages over H1/H1 homozygotes: HDL-cholesterol was 18% higher (p=0.02), fasting triglycerides were 19% lower (p=0.03), and apoB levels — a direct measure of atherogenic particle count — were 21% lower (p=0.002).

A mechanistic clinical study by Pillois et al. 2012⁶⁶ Pillois et al. 2012
Journal of Lipid Research measured apoCI plasma levels and CETP activity simultaneously in coronary artery disease patients, including APOC1 HpaI genotyping as a covariate. ApoCI levels correlated negatively with CETP activity and positively with the HDL/LDL ratio (r=0.359, p<0.001) in normolipidemic patients. Importantly, the CETP-inhibitory function of apoCI was blunted in dyslipidemic patients — those with elevated triglycerides, high cholesterol, or combined hyperlipidemia lost the natural apoCI-CETP brake, underscoring why maintaining normal lipid levels preserves the benefit of higher-expression APOC1 genotypes.

Transgenic studies in hypercholesterolemic rabbits Gautier et al. 2021⁷⁷ Gautier et al. 2021
Atherosclerosis showed that human apoCI expression reduced atherosclerotic lesions by 22% (p<0.05), raised HDL-C, cut specific CETP activity by 14% (p<0.05), and reduced HDL's availability as a CETP substrate by 25% (p<0.05). These atheroprotective effects track directly with apoCI expression levels.

The rs11568822 variant is also in very tight linkage disequilibrium with the APOE ε4 haplotype in European populations (H2 allele frequency is 0.85 with APOE ε4 but only 0.02 with APOE ε3 in European-Americans), which must be accounted for in any analysis. Alzheimer's disease associations attributed to rs11568822 in some studies are explained by this LD pattern with APOE ε4, not by independent APOC1 effects.

Practical Actions

The primary actionable consequence of the H1/H1 (no-insertion) genotype is a modestly reduced APOC1 expression with less endogenous CETP inhibition. This does not prevent you from managing your lipid profile effectively. Dietary omega-3 fatty acids (EPA/DHA) upregulate LCAT and modify HDL particle composition through pathways complementary to apoCI's CETP-inhibitory mechanism. Niacin (vitamin B3) is one of the few clinical agents that raises APOC1 expression alongside HDL-C. Monitoring lipid function with an advanced panel including apoB provides better cardiovascular risk stratification for individuals with lower APOC1 activity.

Interactions

The rs11568822 variant exists within a haplotype block spanning the APOE-APOC1- APOC4-APOC2 gene cluster. APOE genotype (rs429358, rs7412) strongly modulates lipoprotein metabolism in the same pathway — APOE ε4 carriers with H1/H1 have both impaired lipoprotein clearance and reduced apoCI-mediated CETP inhibition, a combination warranting attentive lipid monitoring. The CETP Taq1B variant (rs708272) directly affects CETP enzyme levels and interacts with apoCI concentration in determining the net cholesteryl ester transfer rate. Individuals with low APOC1 expression (H1/H1) who also carry a high-activity CETP genotype face a double reduction in HDL-C from the same pathway. The downstream HCR-2 SNP rs35136575 in the same gene cluster was independently associated with LDL-C and plasma apoE levels in large cohort studies.